The effect of the quadruple regimen containing rosuvastatin on the improvement of stomach infection

Effectiveness of Rosuvastatin -containing quadriple regimen in eradication of Helicobacter pylori infection compared to the standard four-drug regimen in Helicobacter pylori positive patients

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20230314057717N2

Enrollment

156

Registered

2023-06-21

Start date

2023-07-06

Completion date

Unknown

Last updated

2023-06-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Helicobacter pylori. Helicobacter pylori [H. pylori] as the cause of diseases classified elsewhere

Interventions

Intervention 1: Intervention group: Patients in this group received rosuvastatin tablets (20 mg) once a day in addition to quadruple therapy (amoxicillin (1 g), clarithromycin (500 mg), metronidazole

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Confirmation of H. pylori infection in patients by standard diagnostic methods Age above 18 years Willingness to participate in the study

Exclusion criteria

Exclusion criteria: Patients are currently being treated with a four-drug regimen

Design outcomes

Primary

Measure	Time frame
Helicobacter pylori eradication. Timepoint: Before the intervention and 14 days after the intervention. Method of measurement: Endoscopy or fecal antigen test.	—

Secondary

Measure	Time frame
Occurrence of drug side effects. Timepoint: 14 days after the start of the intervention. Method of measurement: Physical examination.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactShahrzad Salimi

Shahid Beheshti University of Medical Sciences

sharzad.salimi6969@gmail.com+98 21 2243 2525

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026